MED

+ Watchlist + Portfolio

MEDIFAST INC

Physical products Consumer brandTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $11.43
52-Week Range: $9.22 – $14.15
Market Cap: $131.15M
P/E (TTM): —
EPS (TTM): -2.33
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.62
PEG Ratio: 0.97
Return on Equity: -12.42%
Return on Assets: -4.60%
Gross Margin: 69.24%
Operating Margin: -5.66%
Profit Margin: -8.08%
Current Ratio: 4.86
Debt/Equity: 0.14
Total Debt: $27.62M
Free Cash Flow: $11.37M
Revenue Growth: -27.60%
Earnings Growth: —
Enterprise Value: $-20.93M

MED Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.60B	$1.07B	$602.46M	$385.79M
Cost of Revenue	$458.16M	$296.20M	$157.84M	$110.60M
Gross Profit	$1.14B	$775.85M	$444.62M	$275.19M
Selling, General & Admin	$955.61M	$649.45M	$441.75M	$289.40M
Operating Expenses	$955.61M	$649.45M	$441.75M	$289.40M
Operating Income	$184.81M	$126.40M	$2.88M	-$14.21M
EBITDA	$195.74M	$139.51M	$15.59M	$29.00K
Pretax Income	$184.06M	$128.80M	$3.79M	-$5.64M
Income Tax	$40.49M	$29.38M	$1.70M	$13.03M
Net Income	$143.57M	$99.42M	$2.09M	-$18.67M
Diluted EPS	12.73	9.10	0.19	-1.70
Diluted Shares	11.28M	10.92M	10.96M	10.98M

MED Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$87.69M	$94.44M	$90.93M	$89.30M
Inventory	$118.86M	$54.59M	$42.42M	$20.23M
Current Assets	$222.78M	$224.03M	$214.40M	$201.68M
Total Assets	$316.21M	$309.91M	$284.21M	$247.97M
Current Liabilities	$140.89M	$92.30M	$64.16M	$42.96M
Total Debt	$26.05M	$22.01M	$16.13M	$10.69M
Total Liabilities	$161.17M	$108.43M	$74.10M	$49.05M
Retained Earnings	$139.85M	$174.65M	$176.78M	$158.27M
Shareholders' Equity	$155.04M	$201.48M	$210.11M	$198.92M
Working Capital	$81.89M	$131.73M	$150.24M	$158.72M

MED Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$194.57M	$147.66M	$24.48M	$6.86M
Capital Expenditure	-$16.68M	-$6.48M	-$7.45M	-$5.61M
Free Cash Flow	$177.89M	$141.17M	$17.02M	$1.25M
Depreciation & Amortisation	$10.98M	$13.11M	$12.71M	$14.24M
Stock-Based Compensation	$11.05M	$8.19M	$7.36M	$7.64M
Investing Cash Flow	-$11.41M	-$61.05M	-$26.52M	-$7.93M
Financing Cash Flow	-$199.58M	-$79.79M	-$1.51M	-$564.00K
Dividends Paid	-$71.62M	-$73.02M	-$715.00K	-$195.00K
Share Repurchases	-$127.96M	-$6.96M	-$836.00K	-$369.00K
Net Change in Cash	-$16.43M	$6.82M	-$3.56M	-$1.63M

MED Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$115.73M	$105.56M	$89.41M	$75.10M	$76.04M	$76.38M
Cost of Revenue	$31.48M	$28.91M	$27.25M	$22.96M	$24.29M	$22.99M
Gross Profit	$84.25M	$76.64M	$62.16M	$52.14M	$51.76M	$53.40M
Selling, General & Admin	$85.51M	$77.71M	$66.24M	$59.94M	$55.05M	$57.72M
Operating Expenses	$85.51M	$77.71M	$66.24M	$59.94M	$55.05M	$57.72M
Operating Income	-$1.26M	-$1.07M	-$4.08M	-$7.80M	-$3.29M	-$4.33M
EBITDA	$2.02M	$2.98M	-$629.00K	-$4.34M	$188.00K	-$881.00K
Pretax Income	$526.00K	$2.88M	-$2.66M	-$6.38M	-$1.94M	-$2.99M
Income Tax	$1.30M	$395.00K	-$396.00K	$11.74M	$181.00K	$109.00K
Net Income	-$772.00K	$2.48M	-$2.26M	-$18.12M	-$2.12M	-$3.10M
Diluted EPS	-0.07	0.22	-0.21	-1.65	-0.19	-0.28
Diluted Shares	10.95M	11.06M	10.99M	10.99M	11.01M	11.13M

MED Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$91.72M	$101.69M	$99.53M	$89.30M	$71.53M	$71.91M
Inventory	$39.36M	$30.20M	$23.20M	$20.23M	$21.40M	$21.18M
Current Assets	$213.52M	$206.44M	$207.84M	$201.68M	$202.63M	$202.03M
Total Assets	$280.01M	$269.33M	$268.21M	$247.97M	$252.05M	$260.40M
Current Liabilities	$60.60M	$46.18M	$46.71M	$42.96M	$42.18M	$41.56M
Total Debt	$14.61M	$13.07M	$12.26M	$10.69M	$16.10M	$27.62M
Total Liabilities	$69.05M	$53.33M	$53.50M	$49.05M	$54.37M	$64.02M
Retained Earnings	$176.01M	$178.49M	$176.24M	$158.27M	$156.15M	$153.05M
Shareholders' Equity	$210.96M	$216.00M	$214.71M	$198.92M	$197.68M	$196.38M
Working Capital	$152.93M	$160.26M	$161.13M	$158.72M	$160.45M	$160.47M

MED Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$3.41M	-$3.38M	$12.11M	-$5.28M	$260.00K	$1.70M
Capital Expenditure	-$1.52M	-$1.38M	-$1.36M	-$1.35M	-$1.10M	-$969.00K
Free Cash Flow	$1.88M	-$4.76M	$10.75M	-$6.63M	-$836.00K	$728.00K
Depreciation & Amortisation	$3.28M	$4.04M	$3.45M	$3.46M	$3.48M	$3.45M
Stock-Based Compensation	$1.93M	$2.63M	$910.00K	$2.17M	$1.90M	$1.82M
Investing Cash Flow	-$2.05M	$13.36M	-$14.28M	-$4.95M	-$17.13M	-$1.23M
Financing Cash Flow	-$563.00K	-$2.00K	$0.00	$1.00K	-$901.00K	-$83.00K
Dividends Paid	-$194.00K	-$1.00K	$0.00	$0.00	-$87.00K	-$83.00K
Share Repurchases	-$369.00K	-$1.00K	$0.00	$1.00K	-$814.00K	$0.00
Net Change in Cash	$789.00K	$9.98M	-$2.17M	-$10.23M	-$17.77M	$381.00K

Market Snapshot

About

Medifast Inc. is a health and wellness company focused on weight management and healthy living solutions. The company primarily operates through its Optavia brand, which offers scientifically developed products and a community-based coaching program to help people achieve and maintain a healthy weight.